VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 92-102

  Mehta, Shrenik ^a   Cuirolo, Arabela X ^a   Plata, Konrad B ^b   Riosa, Sarah ^b   Silverman, Jared A ^c   Rubio, Aileen ^c   Rosato, Roberto R ^b   Rosato, Adriana E ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; DAPTOMYCIN; OXACILLIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CELL WALL; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE EXPRESSION; GENE MUTATION; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MPRF GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION; VRASR GENE;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CELL WALL; DAPTOMYCIN; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC COMPLEMENTATION TEST; GENOTYPE; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROSCOPY, ELECTRON; MUTATION; PHENOTYPE; PLASMIDS; STAPHYLOCOCCAL INFECTIONS; TRANSCRIPTOME; TRANSFORMATION, BACTERIAL;

EID: 84455170136     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00432-10     Document Type: Article

References (49)

1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681. (Pubitemid 38781657)
2. Baltz RH. 2009. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13:144-151.
3. Baltz RH, Miao V, Wrigley SK. 2005. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat. Prod. Rep. 22:717-741. (Pubitemid 41830839)
4. Bannerman TL, Hancock GA, Tenover FC, Miller JM. 1995. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J. Clin. Microbiol. 33:551-555.
5. Bertsche U, et al. 2011. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob. Agents Chemother. 55:3922-3928.
6. Boyle-Vavra S, Yin S, Daum RS. 2006. The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 262:163-171. (Pubitemid 44272791)
7. Camargo IL, Neoh HM, Cui L, Hiramatsu K. 2008. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52:4289-4299.
8. Chambers HF. 1995. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob. Agents Chemother. 39:462-466.
9. Chambers HF. 2005. Community-associated MRSA - resistance and virulence converge. N. Engl. J. Med. 352:1485-1487. (Pubitemid 40471458)
10. Chambers HF, Archer G, Matsuhashi M. 1989. Low-level methicillin resistance in strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 33:424-428. (Pubitemid 19094266)
11. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285. (Pubitemid 30650868)
12. Cuirolo A, Plata K, Rosato AE. 2009. Development of homogeneous expression of resistance in methicillin-resistant Staphylococcus aureus clinical strains is functionally associated with a beta-lactam-mediated SOS response. J. Antimicrob. Chemother. 64:37-45.
13. Dengler V, Meier PS, Heusser R, Berger-Bachi B, McCallum N. 2011. Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in response to different cell wall active antibiotics. BMC Microbiol. 11:16.
14. Ernst CM, et al. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 5:e1000660.
15. Finan JE, Rosato AE, Dickinson TM, Ko D, Archer GL. 2002. Conversion of oxacillin-resistant staphylococci from heterotypic to homotypic resistance expression. Antimicrob. Agents Chemother. 46:24-30. (Pubitemid 34031597)
16. Fischer A, et al. 2011. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. 66:1696-1711.
17. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. (Pubitemid 43807536)
18. Gardete S, Wu SW, Gill S, Tomasz A. 2006. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:3424-3434. (Pubitemid 44527519)
19. Goldstein F, et al. 2007. Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. Antimicrob. Agents Chemother. 51:2514-2522. (Pubitemid 47047331)
20. Gqada Z, et al. 2008. Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. 46:2471-2472.
21. Hachmann AB, Angert ER, Helmann JD. 2009. Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrob. Agents Chemother. 53:1598-1609.
22. Ichihashi N, Kurokawa K, Matsuo M, Kaito C, Sekimizu K. 2003. Inhibitory effects of basic or neutral phospholipid on acidic phospholipid-mediated dissociation of adenine nucleotide bound to DnaA protein, the initiator of chromosomal DNA replication. J. Biol. Chem. 278:28778-28786. (Pubitemid 36935787)
23. Ito T, et al. 2001. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:1323-1336. (Pubitemid 32374098)
24. Jo DS, Montgomery CP, Yin S, Boyle-Vavra S, Daum RS. 2011. Improved oxacillin treatment outcomes in experimental skin and lung infection by a methicillin-resistant Staphylococcus aureus isolate with a vraSR operon deletion. Antimicrob. Agents Chemother. 55:2818-2823.
25. Jones T, et al. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
26. Julian K, et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448. (Pubitemid 350067576)
27. Kennedy AD, et al. 2008. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc. Natl. Acad. Sci. U. S. A. 105:1327-1332. (Pubitemid 351397052)
28. Kuroda M, et al. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49:807-821. (Pubitemid 36918698)
29. Kuroda M, et al. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-1240. (Pubitemid 32539050)
30. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408. (Pubitemid 34164012)
31. Margolis PS, et al. 2000. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. 44:1825-1831. (Pubitemid 30422931)
32. Mishra NN, et al. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2312-2318.
33. Moe PC, Levin G, Blount P. 2000. Correlating a protein structure with function of a bacterial mechanosensitive channel. J. Biol. Chem. 275:31121-31127.
34. Mohedano ML, et al. 2005. Evidence that the essential response regulator YycF in Streptococcus pneumoniae modulates expression of fatty acid biosynthesis genes and alters membrane composition. J. Bacteriol. 187:2357-2367. (Pubitemid 40389134)
35. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob. Agents Chemother. 52:980-990. (Pubitemid 351358377)
36. NCCLS/CLSI. 2007. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8, 8th ed. NCCLS/CLSI, Wayne, PA.
37. Novick R. 1967. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 33:155-166.
38. Oliveira DC, de Lencastre H. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2155-2161. (Pubitemid 34665910)
39. Patel D, et al. 2011. Mechanisms of in-vitro-selected daptomycin-nonsusceptibility in Staphylococcus aureus. Int. J. Antimicrob. Agents 38:442-446.
40. Peschel A, et al. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med. 193:1067-1076. (Pubitemid 32436200)
41. Peschel A, et al. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410. (Pubitemid 29164628)
42. Pillai SK, et al. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51:2223-2225. (Pubitemid 46903123)
43. Rohrer S, Maki H, Berger-Bachi B. 2003. What makes resistance to methicillin heterogeneous? J. Med. Microbiol. 52:605-607. (Pubitemid 36981465)
44. Rosato AE, Craig WA, Archer GL. 2003. Quantitation of mecA transcription in oxacillin-resistant Staphylococcus aureus clinical isolates. J. Bacteriol. 185:3446-3452. (Pubitemid 36617758)
45. Tenover FC, et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
46. Yang SJ, et al. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
47. Yang SJ, et al. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54:3161-3169.
48. Yang SJ, et al. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:2636-2637.
49. Yin S, Daum RS, Boyle-Vavra S. 2006. VraSR two-component regulatory system and its role in induction of pbp2 and vraSR expression by cell wall antimicrobials in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:336-343. (Pubitemid 43042941)